Who Owns ADARx?
ADARx is the brand of ADARx Pharmaceuticals, Inc., the San Diego biotechnology company founded in 2019. The brand covers its next-generation siRNA therapeutic pipeline and delivery platform. The company listed on Nasdaq as ADRX on September 24, 2026.
Parent Company
Founded
2019
Status
Publicly Traded
Headquarters
United StatesOfficial Website
Who Owns ADARx?
- Parent Company: ADARx Pharmaceuticals, Inc.
- Ownership Type: Wholly owned
- Company Type: Publicly Traded
- Stock Ticker: Nasdaq: ADRX
| Brand | Parent Company | Ownership Type |
|---|---|---|
| ADARx | ADARx Pharmaceuticals, Inc. | Wholly owned |
Where to Buy
Disclosure: We may earn commission from purchases
ADARx on AmazonHistory of ADARx
- Founded: 2019
- Founders: Zhen Li
Zhen Li co-founded the company in December 2019 and became CEO in January 2020. The brand emerged from the San Diego biotech cluster with leadership drawn from Arrowhead Pharmaceuticals and Merck.
The brand's public identity formed around its siRNA delivery platform and a pipeline spanning multiple disease areas. The September 2026 Nasdaq listing made ADARx a public brand after six years of private development.
About ADARx Pharmaceuticals, Inc.
What does ADARx do?
ADARx develops siRNA therapeutics that silence disease-driving genes. Its pipeline targets cardiovascular, metabolic, complement, and neurological conditions using delivery technology that reaches tissues beyond the liver.
Is ADARx publicly traded?
Yes. ADARx listed on Nasdaq under ticker ADRX on September 24, 2026, raising approximately $446 million.
Who founded ADARx?
Zhen Li co-founded the company in December 2019 and serves as president and CEO. She previously led siRNA research at Arrowhead Pharmaceuticals and Merck.
Where is ADARx headquartered?
ADARx is headquartered at 5871 Oberlin Drive in San Diego, California.
Who owns ADARx?
After the IPO, ADARx is owned by public shareholders, founders, employees, and venture investors. AbbVie holds approximately 4.9% through an IPO investment capped at $100 million.
When did ADARx IPO?
ADARx priced its IPO on September 24, 2026, selling 26.25 million shares at $17 each for gross proceeds of approximately $446.3 million.
- Founded: 2019
- Headquarters: San Diego, California, United States
- Company Type: Publicly Traded
- Stock: Nasdaq: ADRX
- Employees: ~250
Where Is ADARx Made / Based?
- Headquarters: San Diego, California, United States
ADARx Categories & Tags
ADARx Ownership: Pros & Cons
Advantages
- +Deep technical expertise in siRNA from industry veterans
- +$446 million IPO provides significant funding runway
- +AbbVie's stake signals pharmaceutical industry confidence
Considerations
- -No approved products or product revenue
- -Clinical trial outcomes are inherently uncertain
- -Competes against larger, better-funded RNAi companies
Frequently Asked Questions About ADARx
Sources & Further Reading
- ADARx,
- ADARx Pharmaceuticals company profile, /companies/adarx-pharmaceuticals
Competitors to ADARx
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Amgen | USA | 1980 | Market leader | Global | All-ages |
Learn More About Competitors
Competitive Analysis
Market Positioning: ADARx competes with 1 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Independent Alternatives to ADARx
Looking for brands with different ownership structures? These similar brands are not owned by ADARx Pharmaceuticals, Inc., giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsAmgen
Owned by Amgen Inc.
Master biotechnology brand of Amgen Inc., the world's largest independent biotech, covering its full portfolio of biologic medicines.
biotechnologypharmaceuticalsbiologics
Publicly Traded
Amgen operates independently without a large parent corporation.
Healthcare PharmaceuticalsBoots
Owned by Walgreens Boots Alliance
Boots is the UK's leading pharmacy-led health and beauty retailer, founded in 1849, now operating as The Boots Group under Sycamore Partners since August 2025.
pharmacyhealth-beautyuk-retail
Privately Owned
Boots is privately owned, unlike ADARx which is under a publicly traded parent company.
Healthcare PharmaceuticalsDuane Reade
Owned by Walgreens Boots Alliance
Duane Reade is a New York City drugstore chain owned by Walgreen Co. under Sycamore Partners, operating approximately 90 stores across the five boroughs.
pharmacydrugstorenew-york
Privately Owned
Duane Reade is privately owned, unlike ADARx which is under a publicly traded parent company.
Healthcare PharmaceuticalsPharmacy Direct
Owned by Chempro Chemists
Australian online pharmacy operated by Chempro Chemists from Molendinar, Queensland. Offers prescription medications, health products, and wellness items through digital platforms and mail-order delivery.
online-pharmacymail-orderdigital-health
Privately Owned
Pharmacy Direct is privately owned, unlike ADARx which is under a publicly traded parent company.
Healthcare PharmaceuticalsRetavase
Owned by EKR Therapeutics, Inc.
Retavase (reteplase) is a prescription thrombolytic medication indicated for acute ST-elevation myocardial infarction. Administered as two 10-unit intravenous bolus injections 30 minutes apart. Currently marketed by Chiesi USA.
pharmaceuticalthrombolyticreteplase
Privately Owned
Retavase is privately owned, unlike ADARx which is under a publicly traded parent company.
Healthcare PharmaceuticalsTirosint
Owned by IBSA Institut Biochimique S.A.
IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.
levothyroxinehypothyroidismthyroid
Privately Owned
Tirosint is privately owned, unlike ADARx which is under a publicly traded parent company.
ADARx Pharmaceuticals, Inc. Stock Information
Jobs at ADARx Pharmaceuticals, Inc.
Latest News About ADARx
Related Articles About ADARx
View more articles
News & Updates
Monthly IPO Roundup: October 2026 -- September's Biggest Listings
September 2026 IPOs: Shein raised $1.7B in Hong Kong's largest listing of the year and closed flat, NSE India debuted at a $46B valuation in the country's second-largest IPO, Enflame surged 179% in Shanghai, and Anthropic's $2 trillion S-1 surfaced. Full recap.
Who Brands StaffOct 1, 2026
Ipo RoundupIpoStock Market
Global
Iconic British Brands Now Foreign-Owned
Cadbury is American (Mondelez). Rolls-Royce cars are German (BMW). Jaguar Land Rover is Indian (Tata). HP Sauce is American-Belgian (Kraft Heinz). Discover iconic British brands now foreign-owned. Explore our database.
Who Brands StaffOct 1, 2026
UkBritishBrand Ownership
News & Updates
Monthly M&A Roundup: September 2026 Brand Ownership Changes
September 2026's biggest deals: Nvidia signed its $12.9B Hugging Face acquisition, GE Aerospace agreed to buy CPP for $11.75B, AMD acquired World Labs for $8.2B, Royal Caribbean took a $3B stake in Sandals, LVMH sold Marc Jacobs, and Nestle offloaded its vitamins business for $1B. Full breakdown.
Who Brands StaffOct 1, 2026
M And A RoundupAcquisitionsNews
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Brandpharmaceutical
Abbokinase
Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.
Brand in Healthcare & Pharmaceuticals
thrombolyticurokinase
Brandrsv-vaccine
Abrysvo
Pfizer's respiratory syncytial virus (RSV) vaccine approved for older adults, maternal immunization to protect infants, and younger at-risk adults. Launched 2023.
Brand in Healthcare & Pharmaceuticals
vaccinesmaternal-immunization
Branddermatology
Accutane
Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.
Brand in Healthcare & Pharmaceuticals
acne-treatmentprescription